Business Wire

NY-XYLEM

26.5.2022 12:02:13 CEST | Business Wire | Press release

Share
500 Billion Gallons of Water Prevented from Flooding Communities in 2021, Using Xylem Technology

Solutions from global water technology company Xylem (NYSE:XYL), helped prevent more than 500 billion gallons of polluted water from flooding communities in 2021, according to its annual Sustainability Report . The report highlights the Company’s work with customers and partners to solve the world’s greatest water challenges. It also details Xylem’s progress to reduce its operational footprint, including cutting Scope 1 and 2 greenhouse gas (GHG) emission intensity by 12 percent and water use by 22 percent, versus 2019.

“It’s a great privilege to have a leading portfolio of technologies and services to help our customers and communities solve the water challenges so central to a more sustainable world,” said Patrick Decker, president and CEO of Xylem. “We have a responsibility to make a difference, working alongside our customers and partners, and the communities we all serve. That’s why our sustainability report is more than a set of numbers. It’s a report card on the difference we’re making, together, and a dashboard of progress in our mission to solve water.”

“Last year, we intensified our efforts around three key areas. First, we’re helping our customers become more effective stewards of their water resources, particularly through our digitally enabled solutions and services. Second, we’re addressing climate mitigation by helping decarbonize the water sector through high-efficiency technologies and our own net-zero carbon commitments. Lastly, we continue to work to advance equitable access to clean water and sanitation around the globe.”

Xylem provides advanced solutions and services that enable utilities, industrial companies and other water consumers to optimize their networks while achieving their own sustainability goals. As one of many examples, in 2021, Xylem’s technologies helped customers reuse more than 285 billion gallons of water. Building on its work to accelerate the decarbonization of the water sector, the Company’s solutions helped customers reduce their carbon footprint by 0.73 million metric tons of CO2.

Last year, Xylem formalized its commitment to achieve net zero carbon emissions across its own value chain before 2050. In addition to reducing its Scope 1 and 2 net GHG emission intensity by 12 percent, Xylem is now running more than half its major facilities on 100 percent renewable electricity. In 2021, the Company embarked on an ambitious fleet electrification program which delivered a 31 percent reduction in fleet GHG emissions in Europe in its first year of the program, and cut fleet GHG emissions in the US by 19 percent.

In 2021, amid intensifying severe weather events, Xylem increased its humanitarian support for communities impacted by water-related disasters, providing expertise, technology and equipment to more than 15 countries. Xylem reached 1.4 million people with water education, in large part driven by the launch of a new three-year partnership with UNICEF in India.

“2021 was a year in which we continued to operationalize our sustainability commitments throughout the organization,” said Claudia Toussaint, Xylem’s Chief People and Sustainability Officer. “We built more robust internal reporting and controls, established subject matter expertise across functional areas like product development, operations and supply chain, and integrated sustainability into all that we do — from factory floor to the boardroom. Crucially, we also took steps to structure our workplace in a way that best supports the personal and professional growth of our diverse, 17,000-strong team – the driving force in our mission to solve water.”

Other key highlights detailed in the report, and driving progress toward Xylem’s sector-leading 2025 sustainability goals , include:

  • Engaged nearly 6,000 diverse global youth in water innovation programs such as Xylem Ignite and Stockholm Junior Water Prize, fostering the next generation of water sector talent;
  • Contributed 113,000 employee volunteer hours, with 78 percent of employees participating in activities to solve water in their local communities; and
  • Engaged 400 suppliers in the WASH4WORK pledge for access to safe water, sanitation and hygiene (WASH).

To learn more about Xylem’s sustainability progress, download Making Water’s Future Sustainable .

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com .

The statements included in this press release regarding future performance and results, expectations, goals, plans, strategies, priorities, commitments, and other statements, including those related to social, environmental and sustainability-related matters, that are not historical facts are forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking and other statements in this document regarding our environmental and other sustainability plans and goals are not an indication that these statements are necessarily material to investors or are required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking social, environmental and sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. Forward-looking statements are based upon current beliefs, expectations, and assumptions and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual results to differ materially from the forward-looking statements. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in our risk factors, as they may be amended from time to time, set forth in our filings with the SEC, including in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye